Firehawk<sup>®</sup> Displayed in 2017 Pakistan Live

Karachi, Pakistan – From February 16 to February 18, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") attended the 2017 Pakistan Live in Karachi of Pakistan. The congress attracted around 1,000 professionals and surgeons to participate to improve their understanding in cardiovascular diseases by academic exchange and live cases, and share the latest advancement of cardiovascular interventional treatment. MicroPort® was present with a booth and broadcasted a live case of Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®").
 
On February 17, Professor Rosli Bin Mohd Ali of Malaysia-based IJN National Heart Institute and Dr. Tariq Ashraf, an associate professor of National Institute of Cardiovascular Diseases in Pakistan, presented a live case of Firehawk®. They implanted a 3.5 x13mm Firehawk® in the lesion located in the coronary distal ostium of a 48-year-old male patient, and achieved successful outcome which was well recognized by experts in attendance. The two operators spoke highly of the excellent visibility and trackability of Firehawk® and noted the device offers precise positioning and is easy to reach the lesion.
 
The revolutionary third-generation drug-eluting stent Firehawk® is the result of eight years of research and development of MicroPort® and it is the world's first and only target eluting stent. The device officially entered in the Pakistan market in 2016 after it received approval from the Drug Regulatory Authority of Pakistan ("DRAP") in September. The live case broadcasted in the 2017 Pakistan Live once again proved the outstanding performance of Firehawk® which is expected to provide a more ideal solution for local patients with coronary artery diseases in the future.